Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
- Authors
- Kim, Nam Hoon; Kim, Sin Gon
- Issue Date
- 4월-2020
- Publisher
- KOREAN DIABETES ASSOC
- Keywords
- Cardiovascular diseases; Dyslipidemias; Hydroxymethylglutaryl-CoA reductase inhibitors; Metabolic syndrome; Peroxisome proliferator-activated receptors; PPAR alpha
- Citation
- DIABETES & METABOLISM JOURNAL, v.44, no.2, pp.213 - 221
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- DIABETES & METABOLISM JOURNAL
- Volume
- 44
- Number
- 2
- Start Page
- 213
- End Page
- 221
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/56719
- DOI
- 10.4093/dmj.2020.0001
- ISSN
- 2233-6079
- Abstract
- Fibrates, peroxisome proliferator-activated receptor-alpha agonists, are potent lipid-modifying drugs. 'their main effects are reduction of triglycerides and increase in high-density lipoprotein levels. Several randomized controlled trials have not demonstrated their benefits on cardiovascular risk reduction, especially as an "add on" to statin therapy. However, subsequent analyses by major clinical trials, meta-analyses, and real-world evidence have proposed their potential in specific patient populations with atherogenic dyslipidemia and metabolic syndrome. Here, we have reviewed and discussed the accumulated data on fibrates to understand their current status in cardiovascular risk management.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.